Search

Search Constraints

You searched for: Author/Creator Galanter, Joshua

Search Results

1. A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS. Issue 1 (10th January 2022)

2. A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. (10th December 2021)

3. Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*. Issue 1 (14th November 2022)

5. Dose‐dependent inactivation of airway tryptase with a novel dissociating anti‐tryptase antibody (MTPS9579A) in healthy participants: A randomized trial. Issue 2 (30th September 2021)

6. Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation. (August 2022)

7. Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial. Issue 10 (24th August 2021)

8. Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial. Issue 9 (28th August 2020)

9. Genome-wide methylation data mirror ancestry information. Issue 1 (December 2017)

10. Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers. Issue 5 (26th February 2022)